746 articles in this topic
A completed pilot trial tested humanoid robots and AI predictive models to manage dementia care at home, personalizing treatment pathways.
A new Cell study reveals the fronto-insular circuit as the key mediator of TMS antidepressant effects, opening the door to optimized treatment.
New iPSC and cerebral organoid research shows HSV-1 directly activates neurodegeneration and senescence pathways, supporting the viral hypothesis of Alzheimer's disease.
Plasma p-tau217 accurately detects preclinical Alzheimer's in cognitively normal adults, potentially enabling earlier intervention.
A phase 2 RCT finds ABvac40, a vaccine targeting vascular amyloid-ฮฒ40, is safe and immunogenic in early Alzheimer's patients with no ARIA-E.
ฮฒ-endorphin released during exercise wraps around toxic Aฮฒ aggregates, forming a 'corona' that shields brain cells from Alzheimer's damage.
A 19-year cohort study maps how amyloid and tau shift in CSF across the full Alzheimer spectrum, pinpointing the optimal intervention window.
A Phase 4 RCT tests whether one bevacizumab injection matches two combined doses for neovascular AMD outcomes over 12 months.
From Alzheimer's to Parkinson's, a wave of novel FDA approvals is expanding treatment options for serious neurological conditions.
Psychiatrist Dr. Paul Conti outlines actionable frameworks for overcoming intrusive thoughts, bad habits, and low motivation to build lasting mental wellbeing.
Neurosurgeon Dr. Casey Halpern explains how DBS and AI are reshaping treatment of OCD, addiction, and binge eating disorder.
New research overturns assumptions: dolichoectasia, not stenosis, strongly predicts lacunar stroke and cerebral small-vessel disease progression.
